Association of copeptin levels with patient prognosis and survival in sepsis syndromes: a meta-analysis.
Journal
International journal of surgery (London, England)
ISSN: 1743-9159
Titre abrégé: Int J Surg
Pays: United States
ID NLM: 101228232
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
18
08
2023
accepted:
24
12
2023
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
26
4
2024
Statut:
epublish
Résumé
Sepsis syndromes are a major burden in the ICU with very high mortality. Vasopressin and copeptin are released in response to hypovolemia and have shown potential significance in diagnosing sepsis. To investigate the levels of copeptin in patients with sepsis syndromes and evaluate its relation with patient prognosis and mortality. Four databases were searched for literature published from inception to the 8th of November 2022. Original research articles where copeptin was measured in sepsis patients and compared with controls were included. Data extraction and synthesis: study characteristics, levels of copeptin in the participants, and copeptin assay description were extracted. Levels of copeptin in patients were pooled and compared with controls in terms of the standard mean difference (SMD) generated using a random-effects model. Fifteen studies met the selection criteria. Copeptin levels were significantly higher in patients with sepsis, severe sepsis, and septic shock as compared to controls [(SMD: 1.49, 95% CI: 0.81-2.16, P<0.0001), (SMD: 1.94, 95% CI: 0.34-3.54, P=0.02), and (SMD: 2.17, 95% CI: 0.68-3.66, P=0.004), respectively]. The highest copeptin levels were noted in septic shock patients. The admission copeptin levels were significantly lower in survivors as compared to nonsurvivors (SMD: -1.73; 95% CI: -2.41 to -1.06, P<0.001). Copeptin was significantly elevated in sepsis, severe sepsis, and septic shock. Survivors had a significantly lower copeptin during admission. Copeptin offered an excellent predictability to predict 1-month mortality. Measuring the copeptin in sepsis patients can aid treating physicians to foresee patients' prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Sepsis syndromes are a major burden in the ICU with very high mortality. Vasopressin and copeptin are released in response to hypovolemia and have shown potential significance in diagnosing sepsis.
OBJECTIVE
OBJECTIVE
To investigate the levels of copeptin in patients with sepsis syndromes and evaluate its relation with patient prognosis and mortality.
METHODS
METHODS
Four databases were searched for literature published from inception to the 8th of November 2022. Original research articles where copeptin was measured in sepsis patients and compared with controls were included. Data extraction and synthesis: study characteristics, levels of copeptin in the participants, and copeptin assay description were extracted. Levels of copeptin in patients were pooled and compared with controls in terms of the standard mean difference (SMD) generated using a random-effects model.
RESULTS
RESULTS
Fifteen studies met the selection criteria. Copeptin levels were significantly higher in patients with sepsis, severe sepsis, and septic shock as compared to controls [(SMD: 1.49, 95% CI: 0.81-2.16, P<0.0001), (SMD: 1.94, 95% CI: 0.34-3.54, P=0.02), and (SMD: 2.17, 95% CI: 0.68-3.66, P=0.004), respectively]. The highest copeptin levels were noted in septic shock patients. The admission copeptin levels were significantly lower in survivors as compared to nonsurvivors (SMD: -1.73; 95% CI: -2.41 to -1.06, P<0.001).
CONCLUSION AND RELEVANCE
CONCLUSIONS
Copeptin was significantly elevated in sepsis, severe sepsis, and septic shock. Survivors had a significantly lower copeptin during admission. Copeptin offered an excellent predictability to predict 1-month mortality. Measuring the copeptin in sepsis patients can aid treating physicians to foresee patients' prognosis.
Identifiants
pubmed: 38668663
doi: 10.1097/JS9.0000000000001069
pii: 01279778-202404000-00047
doi:
Substances chimiques
copeptins
0
Glycopeptides
0
Biomarkers
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2355-2365Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ 2007;335:879–883.
Esposito S, De Simone G, Boccia G, et al. Sepsis and septic shock: new definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist 2017;10:204–212.
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 2020;395:200–211.
Stephen AH, Montoya RL, Aluisio AR. Sepsis and septic shock in low- and middle-income countries. Surg Infect (Larchmt) 2020;21:571–578.
Gavelli F, Castello LM, Avanzi GC. Management of sepsis and septic shock in the emergency department. Intern Emerg Med 2021;16:1649–1661.
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–1655.
Liu VX, Fielding-Singh V, Greene JD, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med 2017;196:856–863.
Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017;376:2235–2244.
Evans IVR, Phillips GS, Alpern ER, et al. Association between the New York sepsis care mandate and in-hospital mortality for pediatric sepsis. JAMA 2018;320:358–367.
Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Intensive Care Med 2018;44:925–928.
Caldwell HK, Lee HJ, Macbeth AH, et al. Vasopressin: behavioral roles of an “original” neuropeptide. Prog Neurobiol 2008;84:1–24.
Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001;30:671–vii.
Robertson GL, Mahr EA, Athar S, et al. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973;52:2340–2352.
Preibisz JJ, Sealey JE, Laragh JH, et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983;5(2 Pt 2):I129–I138.
Mu D, Ma C, Cheng J, et al. Copeptin in fluid disorders and stress. Clin Chim Acta 2022;529:46–60.
Mu D, Cheng J, Qiu L, et al. Copeptin as a diagnostic and prognostic biomarker in cardiovascular diseases. Front Cardiovasc Med 2022;9:901990.
Fenske WK, Schnyder I, Koch G, et al. Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers. J Clin Endocrinol Metab 2018;103:505–513.
Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112–119.
Gomes DA, de Almeida Beltrão RL, de Oliveira Junior FM, et al. Vasopressin and copeptin release during sepsis and septic shock. Peptides 2021;136:170437.
Möckel M, Searle J. Copeptin-marker of acute myocardial infarction. Curr Atheroscler Rep 2014;16:421.
Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006;91:4381–4386.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88:105906.
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2 : a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both; 2017.
Chapter 25: Assessing risk of bias in a non-randomized study | Cochrane Training [Internet]. Accessed 22 July 2022. https://training.cochrane.org/handbook/current/chapter-25#_Ref396934606
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:1–10.
Takeshima N, Sozu T, Tajika A, et al. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? BMC Med Res Methodol 2014;14:30.
Ameen A, Abdel Rehim M, Shaaban YH. Endocrine And metabolic alterations may underlie mortality of severe sepsis and septic shock patients admitted to ICU. J Egypt Soc Parasitol 2016;46:109–116.
Assaad SN, Salam MMA, El, et al. The potential of serum copeptin as a prognostic marker of mortality in patients with sepsis, severe sepsis, or septic shock. Egypt J Obesity, Diabetes Endocrinol 2016;2:131.
Battista S, Audisio U, Galluzzo C, et al. Assessment of diagnostic and prognostic role of copeptin in the clinical setting of sepsis. Biomed Res Int 2016;2016:3624730.
Jiang L, Feng B, Gao D, et al. Plasma concentrations of copeptin, C-reactive protein and procalcitonin are positively correlated with APACHE II scores in patients with sepsis. J Int Med Res 2015;43:188–195.
Koch A, Yagmur E, Hoss A, et al. Clinical relevance of copeptin plasma levels as a biomarker of disease severity and mortality in critically ill patients. J Clin Lab Anal 2018;32:e22614.
Kloter M, Gregoriano C, Haag E, et al. Risk assessment of sepsis through measurement of proAVP (copeptin): a secondary analysis of the TRIAGE study. Endocr Connect 2021;10:995–1005.
Lee JH, Chan YH, Lai OF, et al. Vasopressin and copeptin levels in children with sepsis and septic shock. Intensive Care Med 2013;39:747–753.
Lesur O, Roussy JF, Chagnon F, et al. Proven infection-related sepsis induces a differential stress response early after ICU admission. Crit Care 2010;14:R131.
Morgenthaler NG, Müller B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219–226.
Palmiere C, Augsburger M. Copeptin as a diagnostic biomarker for sepsis-related deaths. Peptides 2014;59:75–78.
Schlapbach LJ, Frey S, Bigler S, et al. Copeptin concentration in cord blood in infants with early-onset sepsis, chorioamnionitis and perinatal asphyxia. BMC Pediatr 2011;11:38.
Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500–2504.
Zhang Q, Dong G, Zhao X, et al. Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. Intensive Care Med 2014;40:1499–1508.
Sobhy EM, Naguib MM, Hammad MG, et al. Prognostic value of the biomarker copeptin in critically ill patients with sepsis. Kasr Al Ainy Med J 2016;22:123–128.
Lee S, Song J, Park DW, et al. Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock: a prospective observational study according to the Sepsis-3 definitions. BMC Infect Dis 2022;22:8. doi:10.1186/s12879-021-07012-8. PMID: 34983420; PMCID: PMC8725484.
doi: 10.1186/s12879-021-07012-8